| scholarly article | Q13442814 |
| P50 | author | Daniel R DiStefano | Q92562991 |
| Elizabeth A Thoryk | Q92562995 | ||
| Ningyan Zhang | Q92562998 | ||
| Georgina To'a Salazar | Q55437140 | ||
| Leike Li | Q84427628 | ||
| Zhiqiang An | Q88957278 | ||
| Kalpit A Vora | Q89360579 | ||
| Melanie Horton | Q92562989 | ||
| P2093 | author name string | Benjamin J Doranz | |
| Jennifer M Pfaff | |||
| Weixu Meng | |||
| Andrew J Bett | |||
| Danilo R Casimiro | |||
| Qihui Wang | |||
| Trevor Barnes | |||
| P2860 | cites work | The 3.8 Å resolution cryo-EM structure of Zika virus | Q23680595 |
| Structures of the Zika Virus Envelope Protein and Its Complex with a Flavivirus Broadly Protective Antibody | Q24067948 | ||
| A Rapid and Improved Method to Generate Recombinant Dengue Virus Vaccine Candidates | Q24282617 | ||
| The global distribution and burden of dengue | Q24628768 | ||
| Structure of dengue virus: implications for flavivirus organization, maturation, and fusion | Q24736810 | ||
| Structural basis of potent Zika–dengue virus antibody cross-neutralization | Q24740325 | ||
| Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus | Q25161212 | ||
| Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus | Q26247258 | ||
| Rapid isolation of dengue-neutralizing antibodies from single cell-sorted human antigen-specific memory B-cell cultures | Q26700070 | ||
| A high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitopes | Q26860116 | ||
| A Tetravalent Sub-unit Dengue Vaccine Formulated with Ionizable Cationic Lipid Nanoparticle induces Significant Immune Responses in Rodents and Non-Human Primates | Q27116692 | ||
| Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates | Q27469664 | ||
| Monoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption to Vero Cells | Q27469935 | ||
| Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein | Q27472922 | ||
| Folding and dimerization of tick-borne encephalitis virus envelope proteins prM and E in the endoplasmic reticulum | Q27472959 | ||
| Antibody Recognition and Neutralization Determinants on Domains I and II of West Nile Virus Envelope Protein | Q27477718 | ||
| Epitope Determinants of a Chimpanzee Dengue Virus Type 4 (DENV-4)-Neutralizing Antibody and Protection against DENV-4 Challenge in Mice and Rhesus Monkeys by Passively Transferred Humanized Antibody | Q27485025 | ||
| Type- and Subcomplex-Specific Neutralizing Antibodies against Domain III of Dengue Virus Type 2 Envelope Protein Recognize Adjacent Epitopes | Q27485031 | ||
| Antibodies to Envelope Glycoprotein of Dengue Virus during the Natural Course of Infection Are Predominantly Cross-Reactive and Recognize Epitopes Containing Highly Conserved Residues at the Fusion Loop of Domain II | Q27486409 | ||
| Crystal Structure of Dengue Virus Type 1 Envelope Protein in the Postfusion Conformation and Its Implications for Membrane Fusion | Q27488305 | ||
| Dengue virus neutralization by human immune sera: Role of envelope protein domain III-reactive antibody | Q27489654 | ||
| Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody | Q27490283 | ||
| Serotype-Specific Differences in the Risk of Dengue Hemorrhagic Fever: An Analysis of Data Collected in Bangkok, Thailand from 1994 to 2006 | Q27491001 | ||
| Development of a recombinant tetravalent dengue virus vaccine: Immunogenicity and efficacy studies in mice and monkeys | Q27491049 | ||
| The Development of Therapeutic Antibodies That Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1 | Q27491317 | ||
| Structure of the dengue virus envelope protein after membrane fusion | Q27643009 | ||
| The flavivirus precursor membrane-envelope protein complex: structure and maturation | Q27650164 | ||
| Structure of the immature dengue virus at low pH primes proteolytic maturation | Q27650165 | ||
| Structure of a Dengue Virus Envelope Protein Late-Stage Fusion Intermediate | Q27675461 | ||
| Cryo-EM structure of the mature dengue virus at 3.5-Å resolution | Q27675507 | ||
| Structural insights into the neutralization mechanism of a higher primate antibody against dengue virus | Q27675965 | ||
| Near-Atomic Resolution Cryo-Electron Microscopic Structure of Dengue Serotype 4 Virus | Q27680452 | ||
| The structural basis for serotype-specific neutralization of dengue virus by a human antibody | Q27681306 | ||
| A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface | Q27681319 | ||
| Structural and genetic basis for development of broadly neutralizing influenza antibodies | Q27682070 | ||
| Recognition determinants of broadly neutralizing human antibodies against dengue viruses | Q27697333 | ||
| Clustal W and Clustal X version 2.0 | Q27860517 | ||
| Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity | Q27860703 | ||
| Pathogenesis of dengue: challenges to molecular biology | Q27860978 | ||
| Genomic approaches for understanding dengue: insights from the virus, vector, and host | Q28073351 | ||
| Protective Capacity of the Human Anamnestic Antibody Response during Acute Dengue Virus Infection | Q28119679 | ||
| Mutations of an antibody binding energy hot spot on domain III of the dengue 2 envelope glycoprotein exploited for neutralization escape | Q40348866 | ||
| Dengue vaccine: hypotheses to understand CYD-TDV-induced protection | Q42985743 | ||
| Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study. | Q47584703 | ||
| Antibody-dependent enhancement of severe dengue disease in humans | Q47592202 | ||
| Dengvaxia sensitizes seronegatives to vaccine enhanced disease regardless of age. | Q47898513 | ||
| Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomised controlled trials in Asia and Latin America | Q50167968 | ||
| Double Lock of a Human Neutralizing and Protective Monoclonal Antibody Targeting the Yellow Fever Virus Envelope | Q64132979 | ||
| Dengue | Q85327578 | ||
| Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America | Q89453187 | ||
| Cross reactivity of commercial anti-dengue immunoassays in patients with acute Zika virus infection | Q28833082 | ||
| A structural perspective of the flavivirus life cycle | Q29616269 | ||
| Deciphering key features in protein structures with the new ENDscript server | Q29617219 | ||
| Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein | Q29618169 | ||
| Conformational changes of the flavivirus E glycoprotein | Q29618170 | ||
| Prospects for a dengue virus vaccine | Q29619608 | ||
| Efficient generation of monoclonal antibodies from single rhesus macaque antibody secreting cells. | Q30391848 | ||
| Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation | Q33739796 | ||
| In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection | Q33945441 | ||
| Influence of pr-M cleavage on the heterogeneity of extracellular dengue virus particles | Q34046013 | ||
| Utility, limitations, and future of non-human primates for dengue research and vaccine development | Q34238916 | ||
| Combined effects of the structural heterogeneity and dynamics of flaviviruses on antibody recognition | Q34261496 | ||
| Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop | Q34306877 | ||
| The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein | Q34386384 | ||
| Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease | Q34487028 | ||
| Atomic-level functional model of dengue virus Envelope protein infectivity. | Q35026063 | ||
| Potent dengue virus neutralization by a therapeutic antibody with low monovalent affinity requires bivalent engagement | Q35152094 | ||
| A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus | Q35654743 | ||
| Characterization of a Novel Dengue Serotype 4 Virus-Specific Neutralizing Epitope on the Envelope Protein Domain III. | Q35796610 | ||
| Mutagenesis of the DI/DIII linker in dengue virus envelope protein impairs viral particle assembly. | Q36155587 | ||
| Rhesus Macaque B-Cell Responses to an HIV-1 Trimer Vaccine Revealed by Unbiased Longitudinal Repertoire Analysis | Q36245216 | ||
| HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. | Q36345558 | ||
| An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection | Q36667964 | ||
| Repertoire comparison of the B-cell receptor-encoding loci in humans and rhesus macaques by next-generation sequencing | Q37151457 | ||
| Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine | Q37409489 | ||
| Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates | Q37423499 | ||
| Immune response to dengue virus and prospects for a vaccine | Q37827145 | ||
| The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease | Q37903445 | ||
| The development of therapeutic antibodies against dengue virus | Q38705691 | ||
| A DENV-2-type-specific monoclonal antibody binds to the DENV-complex-reactive antigenic site on envelope protein domain 3. | Q38717789 | ||
| Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus | Q38782718 | ||
| Molecular basis of antibody-mediated neutralization and protection against flavivirus | Q38948606 | ||
| Characterization of a dengue type-specific epitope on dengue 3 virus envelope protein domain III. | Q39707252 | ||
| On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes | Q39876628 | ||
| Prior Exposure to Zika Virus Significantly Enhances Peak Dengue-2 Viremia in Rhesus Macaques | Q40037808 | ||
| Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice | Q40052932 | ||
| A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection | Q40344161 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e1007716 | |
| P577 | publication date | 2019-06-06 | |
| P1433 | published in | PLOS Pathogens | Q283209 |
| P1476 | title | Potent neutralizing antibodies elicited by dengue vaccine in rhesus macaque target diverse epitopes | |
| P478 | volume | 15 |
| Q83225458 | Broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics | cites work | P2860 |
Search more.